191 related articles for article (PubMed ID: 33181159)
1. Predicting the development of adverse cardiac events in patients with hypertrophic cardiomyopathy using machine learning.
Kochav SM; Raita Y; Fifer MA; Takayama H; Ginns J; Maurer MS; Reilly MP; Hasegawa K; Shimada YJ
Int J Cardiol; 2021 Mar; 327():117-124. PubMed ID: 33181159
[TBL] [Abstract][Full Text] [Related]
2. A machine learning-based risk stratification model for ventricular tachycardia and heart failure in hypertrophic cardiomyopathy.
Smole T; Žunkovič B; Pičulin M; Kokalj E; Robnik-Šikonja M; Kukar M; Fotiadis DI; Pezoulas VC; Tachos NS; Barlocco F; Mazzarotto F; Popović D; Maier L; Velicki L; MacGowan GA; Olivotto I; Filipović N; Jakovljević DG; Bosnić Z
Comput Biol Med; 2021 Aug; 135():104648. PubMed ID: 34280775
[TBL] [Abstract][Full Text] [Related]
3. Prediction of cardiac death in patients with hypertrophic cardiomyopathy using plasma adipokine levels.
Akita K; Hasegawa K; Fifer MA; Tower-Rader A; Jung J; Maurer MS; Reilly MP; Shimada YJ
Nutr Metab Cardiovasc Dis; 2024 Jun; 34(6):1352-1360. PubMed ID: 38403486
[TBL] [Abstract][Full Text] [Related]
4. Machine learning-based detection of sleep-disordered breathing in hypertrophic cardiomyopathy.
Akita K; Kageyama S; Suzuki S; Ohno K; Kamakura M; Nawada R; Takanaka C; Wakabayashi Y; Kanda T; Tawarahara K; Mutoh M; Matsunaga M; Suwa S; Takeuchi Y; Sakamoto H; Saito H; Hayashi K; Wakahara N; Unno K; Ikoma T; Sato R; Iguchi K; Satoh T; Sano M; Suwa K; Naruse Y; Ohtani H; Saotome M; Maekawa Y;
Heart; 2024 Jun; 110(14):954-962. PubMed ID: 38589224
[TBL] [Abstract][Full Text] [Related]
5. Prediction of Genotype Positivity in Patients With Hypertrophic Cardiomyopathy Using Machine Learning.
Liang LW; Fifer MA; Hasegawa K; Maurer MS; Reilly MP; Shimada YJ
Circ Genom Precis Med; 2021 Jun; 14(3):e003259. PubMed ID: 33890823
[TBL] [Abstract][Full Text] [Related]
6. [Predicting value of 2014 European guidelines risk prediction model for sudden cardiac death (HCM Risk-SCD) in Chinese patients with hypertrophic cardiomyopathy].
Li WX; Liu LW; Wang J; Zuo L; Yang F; Kang N; Lei CH
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Dec; 45(12):1033-1038. PubMed ID: 29325362
[No Abstract] [Full Text] [Related]
7. The China Hypertrophic Cardiomyopathy Project (CHCMP): The Rationale and Design of a Multicenter, Prospective, Registry Cohort Study.
Du Z; Wang K; Cui Y; Xie X; Zhu R; Dong F; Guo X
J Cardiovasc Transl Res; 2024 Jun; 17(3):732-738. PubMed ID: 38180696
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy.
Kubo T; Baba Y; Ochi Y; Hirota T; Yamasaki N; Kawai K; Yamamoto K; Kondo F; Bando K; Yamada E; Furuno T; Yabe T; Doi YL; Kitaoka H
ESC Heart Fail; 2021 Dec; 8(6):5022-5030. PubMed ID: 34472710
[TBL] [Abstract][Full Text] [Related]
9. Machine Learning for Predicting Heart Failure Progression in Hypertrophic Cardiomyopathy.
Fahmy AS; Rowin EJ; Manning WJ; Maron MS; Nezafat R
Front Cardiovasc Med; 2021; 8():647857. PubMed ID: 34055932
[No Abstract] [Full Text] [Related]
10. Proteomics profiling reveals a distinct high-risk molecular subtype of hypertrophic cardiomyopathy.
Liang LW; Raita Y; Hasegawa K; Fifer MA; Maurer MS; Reilly MP; Shimada YJ
Heart; 2022 Oct; 108(22):1807-1814. PubMed ID: 35351822
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Implication of First-Degree Atrioventricular Block in Patients With Hypertrophic Cardiomyopathy.
Higuchi S; Minami Y; Shoda M; Shirotani S; Saito C; Haruki S; Gotou M; Yagishita D; Ejima K; Hagiwara N
J Am Heart Assoc; 2020 Mar; 9(6):e015064. PubMed ID: 32146896
[TBL] [Abstract][Full Text] [Related]
12. Leveraging Machine Learning Techniques to Forecast Patient Prognosis After Percutaneous Coronary Intervention.
Zack CJ; Senecal C; Kinar Y; Metzger Y; Bar-Sinai Y; Widmer RJ; Lennon R; Singh M; Bell MR; Lerman A; Gulati R
JACC Cardiovasc Interv; 2019 Jul; 12(14):1304-1311. PubMed ID: 31255564
[TBL] [Abstract][Full Text] [Related]
13. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Vriesendorp PA; Schinkel AF; Liebregts M; Theuns DA; van Cleemput J; Ten Cate FJ; Willems R; Michels M
Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):829-35. PubMed ID: 25922410
[TBL] [Abstract][Full Text] [Related]
14. Machine Learning-Based Discrimination of Cardiovascular Outcomes in Patients With Hypertrophic Cardiomyopathy.
Rhee TM; Ko YK; Kim HK; Lee SB; Kim BS; Choi HM; Hwang IC; Park JB; Yoon YE; Kim YJ; Cho GY
JACC Asia; 2024 May; 4(5):375-386. PubMed ID: 38765660
[TBL] [Abstract][Full Text] [Related]
15. Automatic machine learning based on native T1 mapping can identify myocardial fibrosis in patients with hypertrophic cardiomyopathy.
Peng WL; Zhang TJ; Shi K; Li HX; Li Y; He S; Li C; Xia D; Xia CC; Li ZL
Eur Radiol; 2022 Feb; 32(2):1044-1053. PubMed ID: 34477909
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy.
Lu DY; Pozios I; Haileselassie B; Ventoulis I; Liu H; Sorensen LL; Canepa M; Phillip S; Abraham MR; Abraham TP
J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29478967
[TBL] [Abstract][Full Text] [Related]
17. Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy.
Fumagalli C; Maurizi N; Day SM; Ashley EA; Michels M; Colan SD; Jacoby D; Marchionni N; Vincent-Tompkins J; Ho CY; Olivotto I;
JAMA Cardiol; 2020 Jan; 5(1):65-72. PubMed ID: 31693057
[TBL] [Abstract][Full Text] [Related]
18. Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events.
Maurizi N; Passantino S; Spaziani G; Girolami F; Arretini A; Targetti M; Pollini I; Tomberli A; Pradella S; Calabri GB; Vinattieri V; Bertaccini B; Leone O; De Simone L; Rapezzi C; Marchionni N; Cecchi F; Favilli S; Olivotto I
JAMA Cardiol; 2018 Jun; 3(6):520-525. PubMed ID: 29710196
[TBL] [Abstract][Full Text] [Related]
19. Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies.
Maron BJ; Rowin EJ; Casey SA; Link MS; Lesser JR; Chan RH; Garberich RF; Udelson JE; Maron MS
J Am Coll Cardiol; 2015 May; 65(18):1915-28. PubMed ID: 25953744
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of Serum Omentin-1 Levels for the Prediction of Adverse Cardiac Events in Patients with Hypertrophic Cardiomyopathy.
Yıldız SS; Sahin I; Cetinkal G; Aksan G; Kucuk SH; Keskin K; Cetin S; Sigirci S; Avcı İİ; Kilci H; Kiliçkesmez K
Med Princ Pract; 2018; 27(2):107-114. PubMed ID: 29402833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
